author-photo

Josie Montegaard

Harvard University

9

Papers

57

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Venetoclax plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (7)
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

2020 Blood
Show All
- Source
- Cite
- Save
Citations (4)
A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)